45LOW

BIT

BIOTRON FPO [BIT]
Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company's lead antiviral drug is BIT225 for the treatment of SARS-CoV-2, HIV-1, hepatitis C virus, hepatitis B virus (HBV), influenza, and dengue virus infections. The company was incorporated in 1999 and is based in Sydney, Australia.
Healthcare · ASX Small Cap
$0.0030 +0.0%

Updated 26 Mar 2026 · Scores refresh every scan

Score Breakdown

Technical37
Catalyst50
Sentiment50
Fundamental38
Momentum69
Risk Gate35
Get alerts when BIT's score changes
Free watchlist with daily scans for 2,200+ ASX stocks
Track BIT — Free

Active Signals

Bullish Signals

  • MACD momentum is picking up steam
  • Volume surging at 2.2x normal while price falls — heavy selling pressure
  • Beating the Small Ords index — relative strength of 1.12, so it's outpacing the pack
  • Volume-price trend suggests distribution — sellers may be sneaking out while price holds
  • Volatility is expanding fast — choppy price action, so buckle up
  • Low cash runway (3 quarters) - dilution risk
  • Micro-cap ($5-20M) - high risk
  • Sentiment is mixed — no strong consensus either way
  • Positive long-term momentum — up 20% over the past year
  • The bigger volume days are the up days — volume-weighted momentum is positive (2.34%/day)
  • Pre-revenue company — Altman Z-Score not applicable
  • Penny stock risk ($0.003)
  • RBA hiking (-3pts)

Risk Signals

  • Stochastic is stretched into overbought — could need a breather
  • Below the 200-day average — the long-term trend is still working against it
  • Piotroski F-Score weak (3/9, low-confidence approx)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Overseas neutral (-2pts, S&P500 neutral, VIX 25)
Ask Scout AI about BIT
"What's driving BIT's score?" "How does BIT compare to peers?" "Key risks for BIT?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

NONE Investor Update
NONE Hepatitis B Virus Program Update
NONE Half Yearly Report and Accounts

Recent ASX Announcements

2026-03-19 Investor Update
2026-03-17 Hepatitis B Virus Program Update PRICE SENSITIVE
2026-02-26 Half Yearly Report and Accounts PRICE SENSITIVE
2026-02-06 Final Director's Interest Notice
2026-01-29 Supplementary Prospectus

Key Metrics

$8.1M
Market Cap
3.3M
Avg Volume
2.2x
Vol Ratio
$0.00 — $0.01
52-Week Range
N/A
Short Interest
N/A
Cash Runway
-122.6%
ROE
N/A
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 66%
LLeader vs LaggardlaggardRS: 0
IInstitutional Sponsorshipinsufficient_dataInst: 0%
MMarket DirectionneutralNeutral

Sector: Healthcare

Ranked #65 of 117 · Sector avg: 46

View all Healthcare signals →
Related Tickers
ATX 59PNV 56IMM 55EYE 55AHC 55
Compare:BIT vs ATXBIT vs PNVBIT vs IMM
Scout Pro — Deeper Analysis for BIT
Try Pro free for 30 days
Share this analysis

Track BIT and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and conviction scoring for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required